FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 582 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment in Patients with MIBC and Response Can Be Monitored by ctDNA New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation MOST POPULAR High Risk of BCSM at 20 Years in Men with Hormone... March 1, 2024 FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who... March 20, 2025 Toddler Celebrates 11 Months Cancer-Free In Adorable Dance Video With Dad. October 17, 2019 PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous... December 17, 2025 Load more HOT NEWS Increased Risk of Haematologic Malignancies Among Children and Adolescents Exposed to... Tagraxofusp Proves Effective for BPDCN, A Rare Blood Cancer ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21... 2022 ASCO Annual Meeting: Social Services Spending and Cancer Survival, Clinical...
